January 25, 2021

The Niche

Trusted stem cell blog & resources

Michael West

2 min read

Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based therapy developed in Israel.” Cell Cure in its PR on this IND also listed three other key bullet points: “IND filed for Phase I/IIa dose escalation trial in patients …Read More

3 min read

Can Google’s new anti-aging company, Calico, have you Googling at age 140? Don’t sell your burial plot just yet. The idea of anti-aging has been around for a very long time and efforts to combat aging have spanned millennia largely without any success so Calico (apparently short for California Life Company, which sounds more like an insurance company to me) faces long odds. Note too that Calico cats are not known for any particular predisposition to long life. Hmmm. Note that you might find …Read More

3 min read

Who might make a fantastic new CIRM President? The California stem cell community is abuzz with this question. This new President will not only lead CIRM today, but also in all likelihood will steer CIRM in its new incarnation after 2017, what I’ve called CIRM 2.0. At least that would be ideal. CIRM has posted a position/candidate specification document here including a summary of the position that includes this statement: The President of CIRM must be a nationally recognized leader with a vision, scientific credibility, and …Read More

3 min read

BioTime (BTX), via its subsidiary Asterias, has formally purchased the Geron (GERN) embryonic stem cell (ESC) research program and assets. Incidentally, Asterias in nature refers to a genus of sea stars including starfish and you can see it in their logo. Perhaps this was chosen given the amazing regenerative capacity of starfish? You may recall that Geron decided not to continue its ESC program despite having an active, FDA approved early clinical trial underway. There was great concern that the program could die, but …Read More